Replies to post #21038 on Charlotte's Web Holdings Inc (CWBHF)

[Wolf-man jack]

WISE WQLF SAYS; Lets not forget the other two CW Labs collaborators that are now part of the Joel Stanley AJNA Bioscience organization that had been formed and funded by Charlottes Web and now it appears has broken ties with CW Holding Company and his going to benefit from the fruits of the Charlottes Web shareholders. IMO Have Mercy WQLF Ahooooooo

FYI: For further and Quicker Reference. Please go to Sticky Notes for more details YQU Understand. Have Mercy WQLF Ahooooooo

WISE WQLF’s Due Diligence on CW Labs and AJNA Bioscience

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171067686

Jeff Lombardo, PharmD, BCOP
VP Pharmacology

Research Assistant Professor in Translational Pharmacology, University at Buffalo; 20+ years in oncology clinical work



Dr. Joong J Fang Said; Staci Gruber and Orrin Devinsky

Our Scientific Advisory Board

https://www.ajnabiosciences.com/about-us

Staci Gruber, PhD
MCLEAN HOSPITAL - HARVARD
MEDICAL SCHOOL

Director of Cognitive and Clinical Neuroimaging Core; Director of Marijuana Investigations for Neuroscientific Discovery

Orrin Devinsky, MD
Chief Medical Advisor

Director Comprehensive Epilepsy Center at NYU Langone, Lead Investigator for Epidiolex, Professor at NYU Grossman School of Medicine

Gene Morse, PharmD, FCCP, BCPS
UNIVERSITY AT BUFFALO

SUNY Distinguished Professor; Director of Biomedical Sciences, Translational Pharmacology Research Core

Charlotte's Web's CW Labs Announce New Scientific Collaboration Researching Hemp CBD Efficacy

FEBRUARY 26, 2021
Harvard Medical School's Dr. Staci Gruber, Ph.D. is lead investigator


“ Two distinct clinical trials will be overseen by lead researcher/investigator Dr. Staci A. Gruber, Ph. D, Associate Professor of Psychiatry at Harvard Medical School and Director of the MIND program at McLean Hospital in Belmont, Mass. These two studies will investigate the efficacy of a custom-formulated, hemp-derived high-CBD product. Clinical trial results are to be published in 2022. Dr. Gruber is also conducting a number of other studies, including a longitudinal observational study of Veterans who use a Charlotte's Web product.

Dr. Gruber's Marijuana Investigations for Neuroscientific Discovery (MIND) Program, established in 2014, is the first of its kind, and is dedicated to studying the long-term impact of cannabis and cannabinoids for medical and adult use which utilizes various clinical and cognitive tools as well as multimodal neuroimaging techniques.

"We are honored to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials," said Tim Orr, President of Charlotte's Web's CW Labs divison.”

https://investors.charlottesweb.com/press-releases/press-release-details/2021/Charlottes-Webs-CW-Labs-Announce-New-Scientific-Collaboration-Researching-Hemp-CBD-Efficacy/default.aspx

[DarthYoda]

omg, Ajna and SB are obviously the same company. Ajna=Stanley Brothers. They are rebranding and adding psychedelics. Easy peezy for CW compared to the constant speculation of gazillions of nonsensical mergers and acquisitions for the competition that are purely imaginary. Good luck with that. You know this would be a first for the cannabis industry as not even Epidiolex is full spectrum. It's just isolate...

At AJNA, our science team is working to develop the world’s first FDA-approved full-spectrum cannabinoid drug and a robust pipeline of other plant medicines.
We are progressing our leading CBD candidate towards clinical trials in 2023. We are also prototyping candidates for IND-enabling studies based on Psilocybe cubensis and lesser known varieties (i.e. Panaeolus cyanescens, Psilocybe azurescens).

AJNA’s cultivar library is growing, with 60+ subspecies providing opportunities for discovery across a rich diversity of tryptamine alkaloid concentrations and ratios.

https://www.ajnabiosciences.com/our-work